Ignite Creation Date:
2024-05-05 @ 10:18 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01077297
Status:
TERMINATED
Last Update Posted:
2018-07-09
First Post:
2010-02-25
Brief Title:
Tezosentan in Pulmonary Arterial Hypertension
Sponsor:
Idorsia Pharmaceuticals Ltd
Organization:
Idorsia Pharmaceuticals Ltd
Study Overview
Official Title:
Multicenter Open-label Non-comparative Proof-of-concept Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable Chronic Pulmonary Arterial Hypertension Currently Not Treated With Endothelin Receptor Antagonists Phosphodiesterase-5 Inhibitors or Prostacyclines
Status:
TERMINATED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to slow recruitment the study was prematurely discontinued
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multicenter Open-label Non-comparative Proof-of-concept Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable Chronic Pulmonary Arterial Hypertension Currently Not Treated With Endothelin Receptor Antagonists Phosphodiesterase-5 Inhibitors or Prostacyclines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None